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Introduction
CMR has previously shown that left ventricular remode-
ling (LVR) resulting from reperfused myocardial infarc-
tion (MI) is dramatically reduced in iNOS knock-out mice
[1]. However, previous studies using transgenic mice with
cardiac-specific overexpression of iNOS have yielded dis-
parate results. One study reported a benign phenotype
while a second reported that iNOS overexpression
resulted in cardiac fibrosis, hypertrophy and dilatation.
One explanation is that transgenic mice may develop
compensatory mechanisms to down-regulate iNOS over-
expression. Another possiblity is that the phenotype of
iNOS overexpression may be variable in its penetrance
due to limited availability of a necessary co-factor (tet-
rahydrobiopterin).
Purpose
To overcome these limitations, our laboratory modified a
highly-efficient gene transfer system to achieve cardiac-
specific iNOS expression after a single IV injection. The
resulting mice were treated with the natural precursor of
tetrahydrobiopterin (sepiapterin) and CMR was per-
formed to assess the impact of iNOS overexpression on LV
form and function.
Methods
High-efficiency, cardiac-specific gene transfer was
achieved by using a cardiac-specific troponin T (cTnT)
promoter in an adeno-associated viral (AAV) genome
packaged into an AAV9 capsid. Thus the cDNA for murine
iNOS was subcloned behind the cTnT promoter in an
AAV-generating plasmid and packaged into AAV9 capsids
using a system kindly provided by Dr. James M. Wilson
(U. Penn, PA) to create AcTnTiNOS. The resulting viral
particles were purified and viral titers were determined as
genomic particles/ml by real-time PCR. A total of twelve
C57Bl/6 mice were used. Three were injected via jugular
vein with increasing doses of AcTnTiNOS for Western blot
analysis at 4 weeks post-injection. Four mice were simi-
larly injected with 1E+11 AcTnTiNOS particles at 4 weeks
of age for CMR analysis. Starting 10 weeks after vector
injection, these mice were additionally treated for 4 weeks
with sepiapterin (50 μg/day by Alzet micro-osmotic
pump). Another 5 untreated C57Bl/6 mice served as age-
matched controls. CMR was performed at the end of sepi-
apterin treatment to assess the impact of iNOS overexpres-
sion using a 4.7 T Varian system and a black-blood pulse
sequence as described [2]. Excised hearts from the control
and AcTnTiNOS-treated groups were immunostained for
iNOS and for cleaved caspase III (a sensitive marker of
apoptosis).
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Western blots revealed dose-dependent increases in iNOS
protein in the hearts of mice injected 4 weeks earlier with
AcTnTiNOS (Figure 1C). No iNOS protein was detected in
other tissues from the same mice, or in any tissue from
control mice. The results of CMR analysis revealed no sig-
nificant differences between the two groups in: body
mass, LV end-diastolic volume, end-systolic volume,
stroke volume, ejection fraction, heart rate, cardiac output
or LV mass to volume ratios. However, significant differ-
ences (p < 0.05) did exist between the control group (Fig-
ure 1B) and the AcTnTiNOS-treated group (Figure 1C) in
both LV mass (57 +/- 2 vs. 65 +/- 2 mg) and LV mass index
(3.2 +/- 0.1 vs. 3.4 +/- 0.1, respectively). Abundant iNOS
was detected by immunohistochemistry in > 90% of AcT-
nTiNOS-treated cardiomyocytes, whereas no iNOS stain-
ing was evident in the hearts of control mice. Similarly,
apoptosis (i.e., cleaved caspase III) was readily detected in
AcTnTiNOS-treated cardiomyocytes, whereas essentially
no cleaved caspase III was found in control cardiomyo-
cytes (Figure 1D and 1E).
Conclusion
This study demonstrates that gene expression from AAV
vectors can be restricted to the heart, that gene expression
persists for over 3 months, and that high-levels of cardiac
iNOS lead to apoptosis and significant LV hypertrophy.
More generally, this study demonstrates (for the first
time) that cardiac-restricted, direct gene transfer with AAV
vectors can be used in conjunction with CMR to deter-
mine the function of individual genes in the hearts of
intact mammals.
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